Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | FABP1 | P07148 | 1/20 | 0.47 |
| ▸ | FABP6 | P51161 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854220 | 0.79 | MAPT (0.59) | MAPTMEN1HPGDKMT2AMAPK1 | |
| SCHEMBL18809821 | 0.78 | HDAC1 (0.57) | MEN1HPGDKMT2AMAPK1HTT | |
| SCHEMBL22190875 | 0.75 | MAPT (0.64) | MAPTMEN1HPGDKMT2AMAPK1 | |
| SCHEMBL3002504 | 0.75 | MAPT (0.55) | MAPTMEN1HPGDKMT2AMAPK1 | |
| SCHEMBL3115051 | 0.74 | KDM4E (0.40) | MAPTMEN1HPGDKMT2AMAPK1 | |
| SCHEMBL22919180 | 0.74 | LMNA (0.41) | MAPTMEN1HPGDKMT2AMAPK1 | |
| SCHEMBL1753019 | 0.74 | NPC1 (0.86) | MAPTMEN1HPGDKMT2AMAPK1 | |
| SCHEMBL15952526 | 0.74 | HTT (0.82) | MAPTMEN1HPGDKMT2AHTT | |
| SCHEMBL4250052 | 0.73 | KMT2A (0.59) | MAPTMEN1HPGDKMT2AHTT | |
| SCHEMBL15293590 | 0.72 | TGM2 (0.51) | MAPTLMNANPC1RAB9AENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873472-B1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-07-12 | — | — | EP | disclosed |
| US-20200131151-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131151-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | MAPT 354/4885MEN1 2373/4885HPGD 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.